Literature DB >> 9512131

Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats.

Y T Huang1, Y R Cheng, H C Lin, M C Hou, S D Lee, C Y Hong.   

Abstract

Octreotide and propranolol are both effective portal hypotensive drugs in the control or prevention of variceal bleeding. The present study was undertaken to investigate the hemodynamic effects of octreotide and propranolol, alone or in combination, in portal hypertensive rats. Portal hypertension was induced by partial portal vein ligation. Portal hypertensive rats were allocated into one of the four groups: vehicle group (saline, 0.5 ml/day), octreotide group (100 microg/kg/12 hr), propranolol group (30 mg/kg/day), and octreotide (100 microg/kg/12 hr) plus propranolol (30 mg/kg/day) group. Propranolol or saline was administered by gavage, octreotide by subcutaneous injection. Drug was given one day before ligation and continued for eight consecutive days. Systemic as well as splanchnic hemodynamic parameters were measured thereafter. The portal venous pressure, portal tributary blood flow, and cardiac index were significantly reduced by octreotide, propranolol, or octreotide plus propranolol in portal hypertensive rats. Portal territory, systemic, and renal vascular resistances were significantly enhanced, while hepatic arterial blood flow significantly reduced, in the octreotide and octreotide plus propranolol groups as compared to vehicle group. Our results showed that eight-day administration of octreotide, propranolol, or octreotide plus propranolol led to portal hypotensive and antihyperdynamic effects in portal hypertensive rats. Overall, octreotide treatment alone resulted in better antihyperdynamic profiles than propranolol treatment alone. The combination of octreotide and propranolol offered no therapeutic benefits and was slightly less effective than octreotide alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512131     DOI: 10.1023/a:1018866608377

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats.

Authors:  H C Lin; O Soubrane; D Lebrec
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

2.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

3.  Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis.

Authors:  H C Lin; Y T Tsai; F Y Lee; S D Lee; H C Hsia; W J Lin; K J Lo
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

4.  Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats.

Authors:  F Y Lee; L A Colombato; A Albillos; R J Groszmann
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

Review 5.  Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding.

Authors:  D Lebrec
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

Review 6.  Pharmacologic treatment of portal hypertension.

Authors:  F Rodríguez-Pérez; R J Groszmann
Journal:  Gastroenterol Clin North Am       Date:  1992-03       Impact factor: 3.806

7.  Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension.

Authors:  S K Sarin; R J Groszmann; P G Mosca; M Rojkind; M J Stadecker; R Bhatnagar; A Reuben; Y Dayal
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

8.  Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model.

Authors:  R J Kroeger; R J Groszmann
Journal:  Hepatology       Date:  1985 Jan-Feb       Impact factor: 17.425

Review 9.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

10.  Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres.

Authors:  M Chojkier; R J Groszmann
Journal:  Am J Physiol       Date:  1981-05
View more
  2 in total

1.  48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study.

Authors:  D Ludwig; S Schädel; A Brüning; B Schiefer; E F Stange
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

2.  Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension.

Authors:  Lionel Fizanne; Nicolas Régenet; Jianhua Wang; Frédéric Oberti; Frédéric Moal; Jerôme Roux; Yves Gallois; Sophie Michalak; Paul Calès
Journal:  Hepatol Int       Date:  2008-04-12       Impact factor: 6.047

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.